​

BeOne Medicines (ONC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ONC Stock Forecast

BeOne Medicines (ONC) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $401.56, with a high of $451.00 and a low of $367.00. This represents a 11.93% increase from the last price of $358.77.

ONC Stock Rating

BeOne Medicines stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 14 Strong Sell Sell Hold Buy Strong Buy

ONC Price Target Upside V Benchmarks

TypeNameUpside
StockBeOne Medicines11.93%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1722
Avg Price Target$415.00$406.00$402.77
Last Closing Price$358.77$358.77$358.77
Upside/Downside15.67%13.16%12.26%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 267201--28
Sep, 267201--28
Aug, 26820---28
Jul, 268191--28
Jun, 268191--28
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 10, 2026Barclays$415.00$351.0018.23%15.67%
Aug 10, 2026Kalpit PatelWolfe Research$370.00$358.383.24%3.13%
Aug 06, 2026Barclays$407.00$327.5324.26%13.44%
Jul 14, 2026Barclays$403.00$303.9632.58%12.33%
Jul 13, 2026Jefferies$380.00$298.7027.22%5.92%
Jul 07, 2026Truist Financial$416.00$308.4634.86%15.95%
Jul 07, 2026RBC Capital$451.00$309.4645.74%25.71%
Jun 02, 2026Leonid TimashevRBC Capital$436.00$276.4757.70%21.53%
May 15, 2026Leerink Partners$367.00$293.7624.93%2.29%
May 07, 2026Morgan Stanley$395.00$312.0526.58%10.10%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 10, 2026BarclaysOverweightOverweighthold
Aug 10, 2026Wolfe ResearchOutperformOutperformhold
Aug 06, 2026Morgan StanleyOverweightOverweighthold
Aug 06, 2026CitigroupBuyBuyhold
Aug 06, 2026CitigroupOutperformOutperformhold
Aug 06, 2026BarclaysOverweightOverweighthold
Jul 13, 2026JefferiesBuyPositiveupgrade
Jul 13, 2026JefferiesBuyBuyupgrade
Jul 07, 2026RBC CapitalOutperformOutperformhold
Jun 02, 2026RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-10 $-1 $8 $17 $26 $35 Dec 24 Dec 25 Dec 26
Dec 24Dec 25Dec 26
Reported$-6.12$34.19-
Avg Forecast$-5.83$-0.02$5.53
High Forecast$-5.20$2.11$8.75
Low Forecast$-6.62$-3.52$0.75
Surprise %4.97%-171050.00%-

Revenue Forecast

$4B $4B $5B $6B $7B $8B Dec 24 Dec 25 Dec 26
Dec 24Dec 25Dec 26
Reported$3.81B$5.34B-
Avg Forecast$3.77B$4.84B$5.98B
High Forecast$3.78B$4.96B$7.00B
Low Forecast$3.75B$4.71B$5.02B
Surprise %1.07%10.39%-

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 24 Dec 25 Dec 26
Dec 24Dec 25Dec 26
Reported$-644.79M$286.93M-
Avg Forecast$-613.83M$-2.11M$582.26M
High Forecast$-547.50M$222.16M$921.72M
Low Forecast$-697.01M$-370.61M$78.97M
Surprise %5.04%-13726.08%-

ONC Forecast FAQ

Is BeOne Medicines stock a buy?

BeOne Medicines stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BeOne Medicines is a favorable investment for most analysts.

What is BeOne Medicines's price target?

BeOne Medicines's price target, set by 14 Wall Street analysts, averages $401.56 over the next 12 months. The price target range spans from $367 at the low end to $451 at the high end, suggesting a potential 11.93% change from the previous closing price of $358.77.

How does BeOne Medicines stock forecast compare to its benchmarks?

BeOne Medicines's stock forecast shows a 11.93% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for BeOne Medicines over the past three months?

  • October 2026: 25.00% Strong Buy, 71.43% Buy, 3.57% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 25.00% Strong Buy, 71.43% Buy, 3.57% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is BeOne Medicines’s EPS forecast?

BeOne Medicines's average annual EPS forecast for its fiscal year ending in December 2026 is $5.53, marking a -83.83% decrease from the reported $34.19 in 2025..

What is BeOne Medicines’s revenue forecast?

BeOne Medicines's average annual revenue forecast for its fiscal year ending in December 2026 is $5.98B, reflecting a 11.90% increase from the reported $5.34B in 2025.

What is BeOne Medicines’s net income forecast?

BeOne Medicines's net income forecast for the fiscal year ending in December 2026 stands at $582.26M, representing an 102.92% increase from the reported $286.93M in 2025.